Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug ...

Catalent stock faces uncertainty as several pharma companies voice concern about potential limited competition following the ...

The advocacy groups said at the time that the deal could constrain competitors such as Amgen, Pfizer, Roche and AstraZeneca, ...

The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of ...

Catalent, Inc. (CTLT), headquartered in Somerset, New Jersey, is a significant provider in the pharmaceutical and biotech ...

Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised ...

Intra-Cellular Therapies ranks at the bottom for Revenue Growth among its peers. It also has the lowest Gross Profit margin. The company's Return on Equity is negative, indicating lower profitability ...

STAT's Readout LOUD podcast discusses Pfizer's woes, explains RFK Jr.'s 'MAHA' campaign, and mulls the latest about the Novo ...

Current health news covers Roche's opposition to Catalent's takeover, cost analysis of weight-loss drugs like Wegovy, U.S.

In an interview with Technology Networks, Dr. Frederic Cedrone, vice president of corporate innovation at Catalent, discussed the challenges faced and solutions found by companies developing ...